# US 2024/0197816 A1 · Composition and method for prolong survival of transplant and recipient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197816 A1
- Document ID: US20240197816A1
- Status: Published application
- Kind: A1
- Application number: 18/533,699
- Filed: 2023-12-08
- Published: 2024-06-20
- Earliest claimed: 2022-12-08
- Assignees: Novmetapharma Co., Ltd.; Seoul National University R&Db Foundation; Seoul National University Hospital
- Applicants: NovMetaPharma Co., Ltd.; Seoul National University R&DB Foundation; Seoul National University Hospital
- Inventors: Seung Hee Yang; Hoeyune Jung; Jong Min Kim; Yon Su Kim; Heonjong Lee
- Web page: https://patentgrep.com/patent/US20240197816A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/05: Dipeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A treatment of rejection of a transplant by a recipient of the transplant is disclosed. Methods for prolonging transplant survival in a recipient of the transplant, prolonging survival of the recipient, delaying and/or suppressing delayed graft function in the recipient, and/or reducing the amount of an immunosuppressant administered for transplantation. The methods include providing the transplant with a CHP or a pharmaceutically acceptable salt thereof is disclosed. Also provided is a method for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

## Claims

### Claim 1

A method for prolonging survival of a recipient of an allogenic transplant and/or prolonging survival of an allogenic transplant in a recipient thereof, comprising administering to the recipient an effective amount of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof.

### Claim 2 (depends on 1)

The method of claim 1, further comprising providing the allogenic transplant, wherein the transplant is treated with cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof, before being transplanted into the recipient.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising administering an immunosuppressant to the recipient.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof begins 0.5-18 hours or 18-36 hours prior to anesthesia for transplantation of the allogenic transplant in the recipient.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof comprises an administering after transplantation an effective mount of the cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof as a maintenance therapy.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof and the administration of the immunosuppressant are carried out simultaneously, concurrently, or sequentially.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof begins 0.5-18 hours or 18-36 hours prior to anesthesia for transplantation of the allogenic transplant in the recipient.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof comprises an administering after transplantation an effective mount of the cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof as a maintenance therapy.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the allogenic transplant is a tissue, an organ, or cells of lung, liver, kidney, pancreas, heart, intestine, abdominal wall, scalp, uterus, or penile.

### Claim 10 (depends on 3)

The method according to claim 3, wherein the allogenic transplant is a tissue, an organ, or cells of lung, liver, kidney, pancreas, heart, intestine, abdominal wall, scalp, uterus, or penile.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof suppresses an immune reaction to the allogenic transplant in the recipient.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the effective amount of the CHP, a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof is about 0.001-0.005 mg/kg, 0.005-0.01 mg/kg, 0.01-0.02 mg/kg, 0.02-0.04 mg/kg, 0.04-0.06 mg/kg, 0.06-0.08 mg/kg, 0.08-1 mg/kg, 1-5 mg/kg, 5-6 mg/kg, 6-7 mg/kg, 7-8 mg/kg, 8-10 mg/kg, 10-15 mg/kg, 15-20 mg/kg, 20-25 mg/kg, 25-30 mg/kg, 30-35 mg/kg, 35-40 mg/kg, 40-45 mg/kg, 45-50 mg/kg, 50-100 mg/kg, 100-150 mg/kg, 150-200 mg/kg, 200-300 mg/kg, 300-400 mg/kg, 400-500 mg/kg, 500-600 mg/kg, 600-700 mg/kg, 700-800 mg/kg, 800-900 mg/kg, 900-1000 mg/kg, 1000-1100 mg/kg, 1100-1200 mg/kg, 1200-1300 mg/kg, 1300-1400 mg/kg, 1400-1500 mg/kg, 1500-1600 mg/kg, 1600-1700 mg/kg, 1700-1800 mg/kg, 1800-1900 mg/kg, 1900-2000 mg/kg, 2000-2100 mg/kg, 2100-2200 mg/kg, 2200-2300 mg/kg, 2300-2400 mg/kg, 2400-2500 mg/kg, 2500-2600 mg/kg, 2600-2700 mg/kg, 2700-2800 mg/kg, 2800-2900 mg/kg, or 2900-3000 mg/kg.

### Claim 13

A method for suppressing or decreasing an immune response to an allogenic transplant in a recipient thereof, for decreasing a rejection of an allogenic transplant in a recipient thereof, and/or for reducing an amount of an immunosuppressant administered during and/or after transplantation of an allogenic transplant to a recipient of the allogenic transplant, said method comprising administering an effective amount of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof to the recipient.

### Claim 14 (depends on 13)

The method of claim 13, further comprising providing the allogenic transplant, wherein the transplant is treated with cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof, before being transplanted into the recipient.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof begins 0.5-18 hours or 18-36 hours prior to anesthesia for transplantation of the allogenic transplant in the recipient.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof comprises an administering after transplantation an effective mount of the cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof as a maintenance therapy.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the administration of cyclo-his-pro (CHP), a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof and the administration of the immunosuppressant are carried out simultaneously, concurrently, or sequentially.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the allogenic transplant is a tissue, an organ, or cells of lung, liver, kidney, pancreas, heart, intestine, abdominal wall, scalp, uterus, or penile.

### Claim 19 (depends on 13)

The method according to claim 13, wherein the effective amount of the CHP, a pharmaceutically acceptable salt thereof, stereoisomer, or a solvate thereof is about 0.001-0.005 mg/kg, 0.005-0.01 mg/kg, 0.01-0.02 mg/kg, 0.02-0.04 mg/kg, 0.04-0.06 mg/kg, 0.06-0.08 mg/kg, 0.08-1 mg/kg, 1-5 mg/kg, 5-6 mg/kg, 6-7 mg/kg, 7-8 mg/kg, 8-10 mg/kg, 10-15 mg/kg, 15-20 mg/kg, 20-25 mg/kg, 25-30 mg/kg, 30-35 mg/kg, 35-40 mg/kg, 40-45 mg/kg, 45-50 mg/kg, 50-100 mg/kg, 100-150 mg/kg, 150-200 mg/kg, 200-300 mg/kg, 300-400 mg/kg, 400-500 mg/kg, 500-600 mg/kg, 600-700 mg/kg, 700-800 mg/kg, 800-900 mg/kg, 900-1000 mg/kg, 1000-1100 mg/kg, 1100-1200 mg/kg, 1200-1300 mg/kg, 1300-1400 mg/kg, 1400-1500 mg/kg, 1500-1600 mg/kg, 1600-1700 mg/kg, 1700-1800 mg/kg, 1800-1900 mg/kg, 1900-2000 mg/kg, 2000-2100 mg/kg, 2100-2200 mg/kg, 2200-2300 mg/kg, 2300-2400 mg/kg, 2400-2500 mg/kg, 2500-2600 mg/kg, 2600-2700 mg/kg, 2700-2800 mg/kg, 2800-2900 mg/kg, or 2900-3000 mg/kg.
